DNA

Rating neutralTentativeAI Memo

Ginkgo Bioworks

As of 2026-05-20/Confidence low/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

low

Horizon

6‑12m

Key catalyst

Q1 2026 print showed weaker revenue but preserved liquidity • 2026-05-07

Expected move: -14%

Biggest risk

Revenue still fell sharply in Q1, the company remains cash-burning, and the monetization path for autonomous labs is not yet proven, so the stock can stay trapped as a dilution-sensitive story despite the current liquidity cushion.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

If autonomous labs keep converting partner science into repeatable revenue and 2026 cash burn stays within management's reiterated range, Ginkgo can justify some recovery value on the platform story after the Biosecurity divestiture.

Research note

Recommendation

neutral

Confidence

low

As of

2026-05-20

Base target

p=50%

Bull target

$12

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Autonomous-lab scaling and partner traction remain the main long-term option
2026 cash-burn execution is the key financing and runway checkpoint
If autonomous labs keep converting partner science into repeatable revenue and 2026 cash burn stays within management's reiterated range, Ginkgo can justify some recovery value on the platform story after the Biosecurity divestiture.

BearKey bullets

Continuing operations still lost $76.1 million in the quarter, while adjusted EBITDA remained negative at $42 million.
Ginkgo reaffirmed 2026 cash-burn guidance of $(150) million to $(125) million; any deterioration against that range would quickly shift the debate back toward runway and financing risk.
Q1 revenue fell to $19 million from $38 million year over year, and management attributed the decline mainly to program rationalization.

WatchKey bullets

Q1 2026 print showed weaker revenue but preserved liquidity

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $8 (p=50%)

Bull/Bear spread: +29% / -57%

Vs latest close: Bull +29% · Base -14% · Bear -57%

Scenario probabilities

Bull Target: $12 (p=20%)Base Target: $8 (p=50%)Bear Target: $4 (p=30%)

Commentary

News flow is concentrated in the May 7 Q1 filing and press release, with no analyst revision wave or clean consensus update surfaced in the packet. The read stays cautious and tentative: liquidity was preserved and burn guidance was reiterated, but core revenue fell sharply, autonomous-lab monetization is still a longer-dated thesis, and the available peer set is a loose small-cap healthcare screen rather than direct operating comparators [#8-K-2026-05-07][#10-Q-2026-05-07].

As of 2026-05-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Autonomous-lab scaling and partner traction remain the main long-term option
2026 cash-burn execution is the key financing and runway checkpoint

Scenarios

Bull Target (Scenario probability)

$12 / p=20% prob

Base Target (Scenario probability)

$8 / p=50% prob

Bear Target (Scenario probability)

$4 / p=30% prob

Price $9 as of 2026-06-02

Nearest Scenario: Base (∆ 14%)

Targets vs latest close: Bull +29% · Base -14% · Bear -57%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-07
Q1 2026 print showed weaker revenue but preserved liquidity
The May 7 8-K/press release reported Q1 revenue of $19 million, down about 49% year over year, with the decline mainly tied to ongoing program rationalization; continuing-operations net loss was $(76.1) million, adjusted EBITDA was $(42) million, and cash, cash equivalents, and marketable securities were $373 million at March 31, 2026 [#8-K-2026-05-07][#10-Q-2026-05-07].
Prob 95.00% • Move 5.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Autonomous-lab scaling and partner traction remain the main long-term option
2026-12-31
Management said Nebula is the world's largest autonomous lab, is targeting a doubling of its size in 2026, and is seeing Cloud Lab traction from partners such as ProQR and Amazon, which gives the stock a specific platform and partnership milestone to monitor even though near-term revenue remains small [#8-K-2026-05-07].
Prob 55% • Move 13% • Priced-in 40%
2026 cash-burn execution is the key financing and runway checkpoint
2026-12-31
Ginkgo reaffirmed expected total 2026 cash burn of $(150) million to $(125) million after reporting $373 million of cash, cash equivalents, and marketable securities at March 31, 2026, so evidence that burn remains inside that range would support runway credibility while a miss would revive financing concerns [#8-K-2026-05-07].
Prob 60% • Move 8% • Priced-in 55%

Risks

Continuing operations still lost $76.1 million in the quarter, while adjusted EBITDA remained negative at $42 million.
Ginkgo reaffirmed 2026 cash-burn guidance of $(150) million to $(125) million; any deterioration against that range would quickly shift the debate back toward runway and financing risk.
Q1 revenue fell to $19 million from $38 million year over year, and management attributed the decline mainly to program rationalization.
The business is still working through restructuring and discontinued-operations cleanup after the Biosecurity divestiture, which makes trend interpretation and comparability noisy.
The platform thesis depends on a relatively small set of customer and partner relationships, and the 10-Q flags liquidity volatility around equity interests held in customers.

Peers

Symbol	Summary
CTKB	Same-sector small-cap life-sciences tools name; useful only as a loose cap-size and funding-sensitivity comp, not a direct synthetic-biology or autonomous-lab operating peer.
KMDA	Same-sector and similar-market-cap healthcare company from the packet; included only to frame small-cap balance-sheet and execution sensitivity, with limited direct read-through to Ginkgo's platform model.
OCGN	Small-cap biotech peer candidate from the packet that helps frame financing and event-volatility risk, but it is not a direct operating analogue for Ginkgo's lab-infrastructure strategy.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-20

AI Stock Memo: DNA - Ginkgo Bioworks - RankAlpha